A3 adenosine receptor ligand for use for achieving a fat loss effect
AssigneeCan-Fite Biopharma Ltd.
InventorsMotti Farbstein, Inbal Itzhak, Shira Cohen, Pnina Fishman
Life of this patent
Estimating the term…
Abstract
Provided is an A3 adenosine receptor (A3AR) ligand for use in achieving at least one fat loss effect selected from: reducing weight of the subject; reducing body fat mass in the subject; treating obesity in the subject and inhibiting adipocytes proliferation in a subject. The disclosure also concerns pharmaceutical compositions, methods of treatment and kits comprising the A3AR ligand.
Claims5
A method for treating a subject comprising administering to said subject an amount of an A3 adenosine receptor (A3AR) ligand, the amount being effective to achieve at least one fat loss effect selected from:
- reduce weight of the subject;
- reduce body fat mass in the subject
- wherein said fat loss effect refers to reducing adipose tissues that are intended to store fat and excluding ectopic fat,
- wherein said A3AR ligand inhibits adipocyte proliferation, and
- wherein said A3AR ligand is CI-IB-MECA or N-(3,4-Dichloro-phenyl)-2-cyclohexyl-1H-imidazo [4,5-c]quinolin-4-amine (CF602).
Dependencies are inferred from the claim text.